Fluvoxamine in depression

Bradford LD Preclinical pharmacology of fluvoxamine (Floxyrol). Proceedings of the International Symposium on Fluvoxamine in Depressive Disorder, Amsterdam, September 8-9, 1984, pp 13-17... 

Hartter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993 110(3) 302-8. 

Recently an updated review of the pharmacology emd the therapeutic use of fluvoxamine in depressive illness has been published [40]. 

Yoshida, K., Ito, K. etal. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26(2), 383-6. 

Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in depression implications for therapy. J Affect Disord 62 77-91 Ito K, Yoshida K, Sato K, et al (2002) A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry... 

Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7 1115-1119 Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20 105-107 Zanardi R, Serretti A, Rossini D, et al (2001) Factors affecting fluvoxamine antidepressant activity influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50 323-330... 

Other SSRIs may be selected as an alternative to fluvoxamine in the event that fluvoxamine cannot be used. Sertraline is the first option because of efficacy for pediatric GAD (Rynn et ah, 2001) paroxetine is an option because of controlled treatment data for adolescent depression (Keller et ah, 2000) and OCD (see Chapter 39) and fluoxetine is an option because of controlled treatment data for pediatric depression (Em-slie et ah, 1997). Eorazepam is included as a short acting alternative to clonazepam. Nortriptyline, which is less anticholinergic and thus may be better tolerated, is included as an alternative to IMF... 

Amore M, Belhni M, Beradi D, et al Double-blind comparison of fluvoxamine and imipramine in depressed patients. Current Therapeutic Research 446 815-820, 1989... 

Benca RM, Obermeyer WH, Thisted RA, et al Sleep and psychiatric disorders a metaanalysis. Arch Gen Psychiatry 49 651-668, 1992 Benfield P, Ward A Fluvoxamine a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32 313-334, 1986... 

Eysselein V, Eberlein G, Ho FJ, et al An amino-terminal fragment of cholecystokinin-58 is present in the gut evidence for a similar processing site of procholecystokinin in canine gut and brain. Reg Peptides 22 205-215, 1988 Fabre L, Vettraine J, Birkhimmer L, et al Fluvoxamine in the treatment of depression a double-blind comparison with imipramine and placebo in outpatients with major depression. Paper presented at the 18th CINP Congress, Nice, France, 1992... 

J Clin Psychiatry 53 [suppl 10) 8-27, 1992 Harris B, Szulecka TK, Anstee JA Fluvoxamine versus amitriptyline in depressed hospital outpatients a multicentre double-blind comparison trial. British Journal of Clinical Research 2 81-88, 1991... 

Ottevanger EA The efficacy of fluvoxamine in patients with severe depression. British Journal of Chnical Research 2 125-132, 1991 Ottosson J Experimental studies of the mode of action of electroconvulsive therapy. 

Although the efficacy of tricyclic antidepressants in the treatment of unipolar depression is beyond reproach, the side-effect profile of these agents makes them less desirable as first-line therapeutic agents. Introduction of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine in the past decade has revolutionized the treatment of depression universally. The side-effect profile of SSRIs, such as nausea, diarrhea and sexual dysfunction, is considerably more benign than that of tricyclic drugs. Multiple controlled trials have proven the efficacy of SSRIs vs. placebo (Nemeroff, 1994). Recently, a number of SNRIs (serotonin and noradrenaline reuptake inhibitors) and so-called atypical antidepressants have been marketed that may have additional advantages over SSRIs, such as more rapid onset of action (venlafaxine. mirtazapine) and low sexual side-effect potential ( bupropion, nefazodone). Additionally, it appears that venlafaxine may be more efficacious in cases of treatment-refractory depression (Clerc et al., 1994 Fatemi et al., 1999). Finally, in a recent report (Thase et al., 2001),... 

Ottevanger EA. Fluvoxamine and clomipramine in depressed hospitalized patients results from a randomized, double-blind study. Encephale 1995 21 317-321. 

Ware MR Fluvoxamine A review of the controlled trials in depression. J Clin Psychiatry 1997 58(Suppl 5) 15. 

Volkcrs AC, Tulen JH, van den Broek WW, Bruyn JA, Passchier J, Pepplinkhuizen L (2004) Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder. Pharmacopsychiatry 37 18-25... 

A 27-year-old married woman with a borderline personality disorder was admitted to hospital with depression and suicidal ideation (65). Over 3 weeks she was given fluvoxamine in doses up to 150 mg/day, but because of lack of response the dosage was increased to 200 mg/day 3 days later she reported that her sex drive was greater than it had ever been before and that she felt she could not control it. There was no evidence of mania. Within a week of withdrawal of fluvoxamine her sexual desire had returned to its previous level. 

Klok CJ, Brouwer GJ, van Praag HM, Doogan D. Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study. Acta Psychiatr Scand 1981 64(1) 1-11. 

Dosing and Administration. Low initial doses of SSRIs are recommended (see Table 69-11) to avoid stimulatory side effects (e.g., insomnia or nervousness). The initial doses are much smaller than those used in depression and should be maintained for the first week of therapy. Paroxetine can be increased by 10 mg weekly the target dose is 40 mg. The starting dose of fluoxetine is 5 mg/day, with dosage increases every 2 or 3 days to a dosage range of 10 to 20 mg/day by the end of 2 weeks. Fluvoxamine can be increased to 150 mg/day in divided doses over 2 weeks. ... 

The results of the few studies reported above suggest that no pharmacokinetic or pharmacodynamic interactions occur with most SSRIs and alcohol, although modest effects were seen with fluvoxamine and possibly paroxetine. However, most manufacturers of SSRIs suggest that concurrent use with alcohol is not advisable. This is presumably because both drugs act on the CNS and also because of the risk of alcohol abuse in depressed patients. ... 

Miljkovic BI Pokrajac M, Timotijevic I, Vara c V. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxam-ine-Utiiium therapy. Int CUn Psychopharmacol (1997) 12, 207-12. 

Bcttidolfi G, Chautems C, Rochat B, Bertschy G, Baumaim P. Nc i-re xinse to citalopram in depressive patients pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacohgy (Berl) (1996) 128, 421—5. 

Spina E, Pollicino AM, Avenso A Campo GM, Caputi AP. Fluvoxamine-induced alterations in pla a concentrations of imipramine and desipramine in depressed patients. IntJ Clin Pharmacol Res ( 993) 13,167-71. 

---